HLA molecules presenting peptides derived from tumor-associated self-antigens (self-TAA) are attractive targets for T-cell-based immunotherapy of cancer. However, detection of such epitopes is hampered by self-tolerance and limitations in the sensitivity of mass spectrometry. Here, we used T cells from HLA-A2-negative donors as tools to detect HLA-A2-bound peptides from two leukemiaassociated differentiation antigens; CD20 and the previously undescribed cancer target myeloperoxidase. A high-throughput platform for epitope discovery was designed using dendritic cells cotransfected with full-length transcripts of self-TAA and HLA-A2 to allow presentation of all naturally processed peptides from a predefined self-protein on foreign HLA. Antigen-reactive T cells were directly detected using panels of color-coded peptide-HLA multimers containing epitopes predicted by a computer algorithm. Strikingly, cytotoxic T cells were generated against 37 out of 50 peptides predicted to bind HLA-A2. Among these, 36 epitopes were previously undescribed. The allorestricted T cells were exquisitely peptide-and HLA-specific and responded strongly to HLA-A2-positive leukemic cells with endogenous expression of CD20 or myeloperoxidase. These results indicate that the repertoire of self-peptides presented on HLA class I has been underestimated and that a wealth of self-TAA can be targeted by T cells when using nontolerized T-cell repertoires. C ytotoxic T cells (CTLs) selectively kill target cells that express defined peptides in complex with MHC class I molecules on the cell surface. Most tumor-associated antigens (TAA) are wild-type self-proteins, and T cells that recognize peptides from these antigens with high affinity are deleted during thymic development. Thus, the utility of T cells for detection of self-peptides presented on self-HLA is limited by tolerance. This may be one reason why the number of epitopes identified from TAA after 2 decades of intense research amounts to less than 600 (1). The ability to rapidly identify new CTL epitopes would likely facilitate the development of effective immunotherapeutic strategies against cancer.
HLA molecules presenting peptides derived from tumor-associated self-antigens (self-TAA) are attractive targets for T-cell-based immunotherapy of cancer. However, detection of such epitopes is hampered by self-tolerance and limitations in the sensitivity of mass spectrometry. Here, we used T cells from HLA-A2-negative donors as tools to detect HLA-A2-bound peptides from two leukemiaassociated differentiation antigens; CD20 and the previously undescribed cancer target myeloperoxidase. A high-throughput platform for epitope discovery was designed using dendritic cells cotransfected with full-length transcripts of self-TAA and HLA-A2 to allow presentation of all naturally processed peptides from a predefined self-protein on foreign HLA. Antigen-reactive T cells were directly detected using panels of color-coded peptide-HLA multimers containing epitopes predicted by a computer algorithm. Strikingly, cytotoxic T cells were generated against 37 out of 50 peptides predicted to bind HLA-A2. Among these, 36 epitopes were previously undescribed. The allorestricted T cells were exquisitely peptide-and HLA-specific and responded strongly to HLA-A2-positive leukemic cells with endogenous expression of CD20 or myeloperoxidase. These results indicate that the repertoire of self-peptides presented on HLA class I has been underestimated and that a wealth of self-TAA can be targeted by T cells when using nontolerized T-cell repertoires. C ytotoxic T cells (CTLs) selectively kill target cells that express defined peptides in complex with MHC class I molecules on the cell surface. Most tumor-associated antigens (TAA) are wild-type self-proteins, and T cells that recognize peptides from these antigens with high affinity are deleted during thymic development. Thus, the utility of T cells for detection of self-peptides presented on self-HLA is limited by tolerance. This may be one reason why the number of epitopes identified from TAA after 2 decades of intense research amounts to less than 600 (1) . The ability to rapidly identify new CTL epitopes would likely facilitate the development of effective immunotherapeutic strategies against cancer.
MHC molecules can be isolated from cells and the associated peptides eluted for identification by MS. Ultimately, this approach may provide a description of the entire MHC-bound peptide repertoire: the immunopeptidome (2, 3) . This is, however, a daunting task, and it is unclear whether current MS-based protocols already provide the required sensitivity. Indeed, although 100,000-750,000 peptide-MHC class I complexes are expressed for each allelic product on the cell surface (for HLA-A and HLA-B loci) (3, 4) , the largest HLA ligandome identified to date contains 14,065 peptides (5) . In contrast, the predicted number of different HLA class I ligands would be 352,000 using the well-renowned computer algorithm NetMHCpan, considering that on average, 4.4% of all nonamers bind HLA class I (6) and that a cell contains at least 8 × 10 6 distinct nonamers (7). Thus, there is a very large gap between the number of confirmed and predicted HLA ligands.
In the present study, we investigated if the breadth of the selfimmunopeptidome and its utility for T-cell targeting could be evaluated by a combination of three elements. First, because self-tolerance is HLA-restricted, we used T cells from HLA-A*02:01-negative (HLA-A2 neg ) donors as tools to detect selfpeptides associated with allogeneic HLA-A2. Second, to induce reactivity against the entire repertoire of epitopes from selfantigens of interest, autologous dendritic cells (DCs) cotransfected with full-length transcripts encoding the target proteins and HLA-A2 were cocultured with the T cells. In this setting, DCs present a multitude of naturally processed self-peptides from predefined self-proteins on the foreign HLA molecule to a T-cell repertoire that has not been affected by tolerance toward this antigen-MHC combination. Third, to detect antigenreactive T cells directly, we used color-coded peptide-HLA-A*02:01 multimers with content of a large panel of peptides from the target proteins, predicted to bind HLA-A2 by a computer algorithm.
Strikingly, the CTL specificities generated by the approach covered the large majority of epitopes that were predicted by the computer algorithm. Cells reactive with epitopes from the leukemia-associated differentiation antigens myeloperoxidase (MPO) and CD20 were highly peptide-and HLA-specific and responded strongly to target cells endogenously expressing the cognate antigens. These data demonstrate that a wealth of self-epitopes is presented on cancer cells at levels sufficient to allow therapeutic targeting. Thus, the limitations of the self-tolerant T-cell repertoire, rather than a narrow immunopeptidome, are likely to Significance T cells recognize fragments of cellular peptides when presented at the cell surface by HLA molecules. Knowledge of which peptides derived from cellular proteins that are available at the cell surface for T-cell recognition is central to our understanding of T-cell tolerance and immunity. Here, we used alloreactive T cells as tools for detection of self-peptides bound to foreign HLA-A2. Our results indicate that the selfimmunopeptidome is far more diverse than previously estimated. Furthermore, our data demonstrate that such selfpeptides represent highly attractive targets for T-cell-based cancer immunotherapy. explain why the known epitope repertoire of many self-antigens of potential clinical interest is still very small. By circumventing this limitation, the approach outlined here should facilitate design of efficient immunotherapy strategies in cancer.
Results
Discovery of 36 Epitopes in the Tumor-Associated Antigens CD20 and MPO by High-Throughput Induction of Allorestricted CTLs. We hypothesized that T-cell repertoires that had not been rendered tolerant would allow efficient and sensitive assessment of the immunopeptidome. This was tested in a setting where peptide presentation of self-antigens by foreign HLA was induced using mRNA transfection of full-length target proteins. Monocytederived DCs from HLA-A2 neg donors were transfected with HLA-A2, which we have demonstrated is an efficient strategy for peptide presentation on allogeneic HLA (8) . The monocytederived DCs (moDCs) were cotransfected with mRNA encoding full-length CD20 or MPO, representing leukemia-associated antigens with an expression pattern confirmed to be highly restricted to normal and malignant hematopoietic cells across 10,000 samples (genesapiens.org). Autologous CD8 pos T cells that had been cocultured with engineered moDCs were labeled with a panel of color-coded peptide-HLA-A2 (pHLA) multimers containing peptides from CD20 or MPO that were predicted to bind HLA-A*02:01 (Fig. 1) . A total of 50 peptides, ranked as strong to intermediate binders (<500 nM) (Table S1) , were synthesized and used to generate pHLA multimers for T-cell staining (Fig. 1A) . Strikingly, pHLA multimer staining revealed that coculture of T cells with CD20-transfected moDCs resulted in generation of T cells reactive with the majority of the 20 peptides from CD20 (Fig. 1B, blue bars) . Specificity of this interaction was shown by the fact that these peptides were not recognized by T cells primed by MPO-transfected DCs ( In summary, the approach resulted in detection of 14/20 of the predicted CD20 epitopes and 23/30 of the predicted MPO epitopes. Of the 37 identified epitopes, 36 were previously undescribed. The generated CTLs reacted only with relevant pHLA multimers and not with a large number of irrelevant peptides, indicating the specific induction of these reactivities exclusively in the presence of the relevant antigen.
Allorestricted CTL Lines Recognize Peptides Presented on Leukemic and Nonmalignant Hematopoietic Cells Endogenously Expressing
CD20 or MPO and are Highly Peptide-and HLA-Specific. Dendritic cells are the most effective antigen-presenting cells known, and it seemed possible that transfected cells might present peptides that are not found on HLA molecules on leukemic cells. To assess whether the epitope repertoire was equally broad on cells endogenously expressing these target proteins, we randomly selected 13 out of the 37 multimer-reactive CTL populations for sorting, expansion of CTL lines, and functional testing. The CTL lines were tested for reactivity against a panel of up to 15 HLA-A2 pos target cells that were positive or negative for CD20 and/or MPO, respectively.
The CTL lines reactive to four different peptides from CD20 responded strongly by degranulation and IFN-γ production to HLA-A2 pos target cells endogenously expressing CD20 ( Fig. 2 A and B). These included EBV-transformed lymphoblastoid cell lines (EBV-LCLs) and the B-prolymphocytic leukemia cell line JVM-2, but also CD20/HLA-A2-transfected HeLa cells ( Fig. 2 A  and B ). Reactivity was also tested against a variety of cell lines of different histologies that expressed HLA-A2, but not CD20, such as colon carcinoma (HCT-116, Caco-2), liver carcinoma (Hep G2), lung adenocarcinoma (NCI-H522), keratinocytes (HaCaT), malignant melanoma (FM81), HEK, cervix adenocarcinoma (HeLa), T-cell lymphoblastic lymphoma (SupT1), chronic myelogeneous leukemia (K562), and mesenchymal stem cells (MSC) (Fig. 2B ). Importantly, no or only very low reactivity was seen against this wide range of targets ( Fig. 2 A and B) . However, responses against these target cells were again observed when the cells were loaded externally with the relevant peptide. Furthermore, the four CD20-reactive CTL lines did not respond to the acute myelomonocytic leukemia cell line THP-1, unless loaded with relevant CD20 peptides (Fig. S1A) .
Similarly, CTL lines reactive to seven different peptides from MPO responded strongly by degranulation and IFN-γ production to HLA-A2 pos target cells that endogenously express MPO: primary monocytes and the acute myelomonocytic leukemia cell line THP-1. Furthermore, these CTL lines also responded to MPO/HLA-A2-transfected HeLa cells. In contrast, antigen-negative target cell lines, whereas responses in all cases again became apparent when these target cells were loaded with the relevant MPO peptide (Fig. 3) .
CTL lines reactive to two additional MPO-derived peptides were generated from the same donor and tested functionally against a smaller selection of target cells in separate experiments. These CTL lines responded strongly to HLA-A2 pos target cells endogenously expressing MPO, either naturally (monocytes, THP-1) or following genetic introduction (SupT1, HeLa), and to HLA-A2 pos MPO neg target cells loaded with relevant peptide (SupT1, T2, HEK, CD4 pos T cells) ( Fig. S1 B and C) . Negligible responses were seen to the MPO neg target cells in the absence of added antigen. Furthermore, strong responses and a high degree of specificity was confirmed for additional cell lines generated against five of the same MPO-derived peptides from a second donor (Fig. S1 D and E) .
To obtain more information on the range of T-cell reactivities to one of the T-cell epitopes discovered here, T-cell clones were generated from CTL line #25, specific for MPO epitope LIQPFMFRL. All CTL clones responded strongly to HLA-A2 pos monocytes, whereas the responses to MPO-transfected or peptide-loaded HEK cells were variable, although in all cases higher than that observed for untransfected HEK cells (Fig. S2A) . Sufficient cells were available for three T-cell clones to evaluate their fine specificity by comparing functional responses to target cells loaded with peptide #25 with those obtained when each amino acid was singly replaced with an alanine residue. All clones responded strongly to the wild-type peptide (57-98% of responding cells). The results showed that for all clones the response was greatly diminished or abolished for peptides with alanine substitutions in one of six or seven positions (Fig. S2B) . The responses to peptides with substitutions in positions 2 and 9 were only partly reduced or not reduced. This is likely due to increased peptide binding to HLA-A2, as amino acids in positions 2 and 9 mediate the anchoring to HLA-A2.
The strong pHLA multimer binding and CTL responses that were induced to various target cells suggested high functional avidities. The CTL lines are, however, likely to consist of T-cell clones displaying a wide variety of reactivities, as previously shown for allorestricted T-cell clones (9) and here for clones recognizing peptide #25. Nevertheless, when performing peptide titrations, reactivity was demonstrated at the lowest concentration (100 pM) for all but one of the tested CTL lines, suggesting that for all, or nearly all, epitopes, highly sensitive T-cell populations can be obtained (Fig. S3) .
In conclusion, we here demonstrate that a total of 18 CTL lines, reactive to 13 different peptides, strongly recognize their cognate antigens but do not show detectable cross-reactivity against a large set of target cells that do not express this antigen. In addition, reactivity against 24 other CD20-and MPO-derived epitopes was observed, which was not pursued further here. Collectively, these results demonstrate that the majority of the algorithm-predicted peptides for CD20 and MPO were presented on the surface of cells endogenously expressing these proteins, thereby forming a broad repertoire of potential T-cell targets. Moreover, the strong target reactivity and high degree of HLA and peptide specificity suggests that such alloreactive CTLs or their T cell receptors (TCRs) could be useful in a therapeutic setting.
Discussion
The results in the present study indicate that the self-immunopeptidome is more diverse than previously believed and that a multitude of self-epitopes can be targeted by T cells. A surprisingly high fraction (74%) of peptides predicted to bind HLA from self-TAA were efficiently presented to CTLs using the strategy presented here (Fig. 4) . This resulted in the detection of 37 epitopes from one known (CD20) and one previously undescribed (MPO) cancer target, representing leukemia-associated differentiation antigens. Among these, 36 epitopes were discovered here. This output was striking, considering that only 250 HLA class I CTL cancer epitopes have been identified to date from nonmelanoma-associated antigens (1). The epitopes identified in the present study were presented on leukemia cells and other target cells endogenously expressing the antigens at levels sufficient to be efficiently recognized by T cells. These results indicate that algorithm-based predictions reflect the immunopeptidome more accurately than previously believed. Furthermore, it suggests that studies performed using mass spectrometry may underestimate MHC-associated peptide repertoires. Peptide ligands for HLA-A*02:01 have not been identified from the large majority of the on average 18,000 proteins expressed in a cell (10) . In concert with this, none of the 36 epitopes from CD20 and MPO that were discovered here were found in existing peptide databases, such as Syfpeithi (syfpeithi.de) and the Immune epitope database (iedb.org).
Our results have important implications for T-cell epitope discovery. Traditional cell-based methods typically involve cloning of patient T cells, followed by laborious screening of clones for reactivity against peptide libraries or fractions of peptide pools eluted from MHC molecules of target cells, and finally peptide characterization by MS (11, 12) . Recently, colorcoded pMHC multimers (13) were used to screen tumorinfiltrating lymphocytes for reactivity against hundreds of known melanoma epitopes, thereby increasing throughput (1). However, all studies depending on patient cells for epitope discovery are limited by tolerance to self and previous immunization history of the individual. In contrast, the strategy presented here took advantage of induction of responses in T-cell repertoires from antigen-inexperienced, nontolerized individuals. This suggests that the use of self-tolerant T-cell repertoires, rather than poor peptide presentation, is the reason why few cancer epitopes have been identified. In the current approach, induction of T-cell responses by DCs transfected with mRNA encoding full-length target proteins focused discovery on naturally presented peptides (14) . Finally, detection of antigen-specific T cells by color-coded pHLA multimers complexed with in silico-predicted peptides secured high throughput.
The discovery of epitopes in self-TAA was based on alloreactive T cells. The concept that cancer cells can be targeted by T cells recognizing self-peptides presented by foreign HLA was first described by Stauss and coworkers (15) (16) (17) . Although these and other studies have shown that certain peptides can be specifically recognized when presented on allogeneic HLA (8, 9, 12, (18) (19) (20) (21) (22) (23) , it seemed possible that they represented exceptions, because there is also evidence that allorestricted cells are more promiscuous with regard to peptide recognition (9, 18, (24) (25) (26) (27) (28) . However, when assessing reactivity to a large number of epitopes at the single-cell level, we did not find evidence suggesting that peptide recognition on foreign HLA generally has a low specificity. First, T cells stimulated by CD20 or MPO did not react with large panels of irrelevant pHLA multimers. More importantly, functional responses were absent or very low when stimulating the CTL lines with a large panel of HLA-A2 pos CD20 neg / MPO neg target cells, representing different histologies and presenting thousands of peptides from endogenously expressed antigens (29) in addition to a wide range of allogeneic HLA molecules. In contrast, these target cells elicited efficient CTL degranulation when induced to express the relevant antigens or loaded with peptide. Finally, the CTLs responded strongly when incubated with leukemia cells and other target cells naturally expressing CD20 or MPO. Importantly, the results did not only reflect the characteristics of a few selected clones but were representative of CTL lines reactive with 13 different peptide targets derived from two proteins. Collectively, the results from this study therefore support the view that specific peptide recognition on foreign HLA is the rule rather than the exception.
The adoptive transfer of donor-derived T cells to a patient in allogeneic hematopoietic stem-cell transplantation can induce remission of leukemia by so-called graft-versus-leukemia effects (30) . A requirement to avoid potentially detrimental graft-versushost disease is that the donor and recipient are HLA-matched. However, recent studies show that clinically beneficial T cells can be generated from a single donor for adoptive transfer to multiple patients that are only partially HLA-matched (31) . Surprisingly, third-party EBV-specific T cells can eliminate EBV-associated posttransplantation lymphoma despite likely immune recognition and rejection of foreign HLA by the patient immune system (31) . Interestingly, there is no evidence that such mismatched CTLs reactive to EBV (32) (33) (34) (35) or cytomegalovirus (36) cause graftversus-host disease. These results, and the results presented here, bear promise that antigen-specific allogeneic T cells reactive to self-TAA can be generated from a single HLA-A2 neg donor for transfer to multiple HLA-A2 pos patients. Alternatively, their receptors may be genetically transferred to redirect patient T cells to the tumor (37) (38) (39) .
Elimination of normal and malignant B cells by anti-CD20 antibody treatment is well tolerated by patients. This suggests that the cytotoxic effects of CD20-specific T cells, although mechanistically different from that of antibodies, would also be tolerated. In contrast, the removal of myeloid cells in leukemia by MPO pos /HLA-A2 pos -specific T cells would result in significant toxicity unless accompanied by an allogeneic hematopoietic stem-cell transplant from an HLA-A2 neg donor. Such transplants, mismatched for one major HLA antigen, are accepted for high-risk patients in the clinic today and would allow retreatment of a potential relapse with MPO-specific T cells while sparing the transplanted cells. The outlined platform for high-throughput epitope discovery provides an important solution to the first bottleneck in the clinical translation of the described concept and warrants further testing of safety and efficacy in vivo.
Materials and Methods
Healthy Donors and Cell Lines. This study was approved by the Regional Ethics Committee and performed in accordance with the declaration of Helsinki. Healthy donors were HLA-typed by standard molecular techniques. Sources and culture conditions for target cell lines are described in SI Materials and Methods.
Prediction of HLA-A*02:01-Specific Peptides from Target Proteins. Protein sequences were obtained from National Center for Biotechnology Information Entrez engine. Prediction of HLA-A*02:01-binding peptides from target proteins was performed using the algorithms NetMHCpan 2.2 (6) for MPO or NetMHC 3.2 (40) for CD20. Peptides with an IC50 score of <500 nM were considered potential HLA-A2 binders and are listed in Table S1 .
Generation of Peptide-HLA Complexes. All predicted peptides and control peptides ELAGIGILTV (MART-1) and NLVPMVATV (CMV) were synthesized by Proimmune, Ltd., or GenScript, Inc. Synthesis of conditional HLA-A2 ligands containing a UV-sensitive peptide was performed as described in refs. 13 and 41. For generation of pMHC multimers, fluorochrome-streptavidin (SA) conjugates were generated as described in ref. 13 , with phycoerythrin (PE), allophycocyanin (APC) (BD Biosciences), or Peridinin-chlorophyll proteinCy5.5 (PerCP-Cy5.5) (Ebiosciences). HLA-B*08:01-and HLA-B*07:02-restricted pentamers were from ProImmune, Ltd.
Plasmid Constructs, mRNA/DNA-Transfection, and Retroviral Transduction. MPO was amplified from reverse-transcribed mRNA from HL-60 cells with Pfx (Invitrogen) using the primers: 5′-caccATGGGGGTTCCCTTCTTC -3′ and 5′-TCAGGCGTAGTCGGGCACGTCGTAGGGGTAGGAGGCTTCCCTCCAGGAAG -3′, subcloned into pENTR/D-TOPO (Invitrogen), and recombined into the Gateway-compatible pCIpA102-G vector for mRNA production following sequencing (42) . The CD20 mRNA expression construct was reported in ref. 23 . The mRNA encoding HLA-A*02:01 or target proteins was generated as described in ref. 8 and used to transfect moDCs, EBV-LCL, HaCaT, or K562 cells by electroporation (1250 V/cm for 3 ms (moDCs, HaCaT), 2 ms (K562), and 1 ms (EBV-LCL), respectively) with a BTX ECM 830 square-wave electroporator (BTX, Harvard Apparatus). HEK and HeLa cells were transfected with Fig. 4 . Platform for high-throughput epitope discovery (1). Candidate target proteins were screened for cell-type-specific expression in normal and malignant hematopoietic cells (genesapiens.org) (2) . Selected target proteins and HLA-A*02:01 were cloned into a vector for in vitro production of mRNA encoding full-length protein (3). Monocyte-derived dendritic cells from HLA-A2 neg donors were transfected with the mRNA and subsequently cocultured with autologous, nonadherent peripheral blood mononuclear cells. The cultures were restimulated with EBV-LCLs transfected with mRNA encoding target protein and HLA-A2 on days 12 and 19 (4) . Selected targets were subjected to affinity-based algorithmic prediction of HLA-A*02:01-restricted peptides (cbs.dtu.dk/ services/NetMHC/), and those predicted to bind with the highest affinities were synthesized (5). Peptides were complexed with HLA-A*02:01 monomers by UV-induced ligand exchange, followed by multimerization using streptavidin (SA) conjugated to PE, APC, or PerCP-Cy5.5, respectively (6) . By end of culture, CD8 pos T cells reactive to different epitopes were detected by flow cytometric measurements of combinations of fluorescently labeled pHLA-A2 multimers.
DNA encoding HLA-A2 and MPO or CD20 using FuGENE-6 (Roche), following the manufacturer's protocol. Retroviral particles were produced and transduced as described in ref. 42 . A Gateway-compatible version of pMP71 was used to express MPO and/or HLA-A*02:01 in SupT1, and the MART-1 (DMF5) TcR in primary T cells [construct derived from pMSGV-DMF5_2A, a kind gift from R. Morgan (National Institutes of Health, Bethesda, MD)].
Induction of Multimer-Reactive T Cells Restricted by Allogeneic HLA. Mature moDCs were generated, as described in ref. 8 , from HLA-A*02:01 neg donors. One hour following mRNA transfection, cells were combined with thawed, autologous nonadherent peripheral blood mononuclear cells (PBMC) and cultured as described in refs. 8 and 23. Cells were restimulated on days 12 and 19 with irradiated (25 Gy) HLA-A*02:01 pos EBV-LCL transfected 4 h earlier with mRNA encoding the target protein, in X-vivo 20 medium (BioWhittaker, Lonza) with 5 ml pooled human serum (Trina Bioreactives AG, Nänikon) per 100 ml medium and with IL-2 supplemented at 10 U/mL on day 14 (R&D Systems).
Multimer Staining and Sorting and Expansion of Multimer-Reactive CTL Lines. On day 26, cocultures were stained with the succinimidyl ester dye Pacific Blue (Invitrogen Molecular Probes) for live/dead cell discrimination at a final concentration of 0.1 μg/mL for 10 min at 37°C in PBS. Two μL of 1-3 pHLA-A*02:01 tetramer(s) (in-house) were added for 15 min at RT to stain 1 × 10 6 cocultured cells, followed by anti-CD8. Sorting was performed using FACS Aria or FACS Vantage SE Cell sorters (BD Biosciences). Sorted, tetramerpositive cells were expanded in the presence of irradiated allogeneic PBMC in X-Vivo 20 medium with 5 ml pooled human serum per 100 ml medium, IL-2 (50 U/mL, R&D Systems), IL-15 (2 ng/mL, Peprotech EC Ltd.), and phytohemagglutinin (PHA) (1 μg/mL, Remel) for 3-4 wk.
Antibodies and Flow Cytometry. Cells were labeled with the following antibodies, in-house conjugated to Alexa Fluor 647 or Atto 488: anti-CD8 (RPA-T8), -CD107a (H4A3), -CD107b (H4B4) (all from BD Biosciences), and -HLA-A2 (BB7.2; AbD Serotec), or -CD4FITC, -MPO-PE (MPO-7; Dako, Denmark), -CD14PerCP-Cy5.5, -IFN-γPE, CD8PerCP-Cy5.5 or CD8Pacific Blue (SK1, Ebiosciences). Cells were analyzed on FACS LSR II, and data analysis was performed with FACS DiVa (both from BD Biosciences) or FlowJo software (Tree Star, Inc.). Functional T-cell responses were measured as mobilization of CD107a/b (degranulation) and production of IFN-γ by flow cytometry, as described in ref. 23 , following coculture with various target cells that were DNA-transfected 48 h earlier, mRNA-transfected 4-10 h earlier, or peptideloaded at 10 μM or indicated concentration for 4-12 h. CD4 pos T cells were isolated using a CD4-positive isolation kit (Dynal Biotech), whereas monocytes were isolated by elutriation centrifugation.
